Pancragen Peptide Dosage Chart: 2mg Course vs Studies

Pancragen is the synthetic tetrapeptide Lys-Glu-Asp-Trp (KEDW), and it is the rare Khavinson bioregulator with a published dose. That dose is in micrograms. Old rhesus monkeys received 50 mcg a day, and a small study in older adults with type 2 diabetes used a 10 mcg daily injection. The widely shared practitioner protocol for all bioregulators is far higher: 2mg (20 units of a 20mg vial with 2mL of bacteriostatic water) once daily for 30 days, then two months off, two to three times a year.

That gap is the main point of this guide. The study doses and the vial-based protocol differ by a factor of about 200, and the vial protocol was not derived from Pancragen research. Everything below labels which number comes from where.

Research-context information only. Pancragen is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Pancragen is a four-amino-acid peptide from the St. Petersburg bioregulator program. The developers derived its sequence from a fragment shared by several insulin-related polypeptides (Khavinson, 2005, PMID 16671579). This guide covers the reported course, the study doses and the reconstitution math.

Quick Reference: Reported Protocols

Where the 2mg figure comes from: it is the shared bioregulator line in a practitioner peptide reference (the Jay Campbell / Hunter Williams cheat sheet), not a Pancragen trial dose. For the compound profile and current vendor pricing, see the Pancragen peptide page.

Cycling Details

The published Pancragen studies used short courses: 10 days in the monkey work and 3 weeks in the human study. In the monkeys, part of the effect on pancreatic function was still present three weeks after dosing stopped (Goncharova et al., 2014, PMID 25946840). That persistence fits the bioregulator idea of a short course followed by a break. Practitioner references stretch the course to 30 days with two months off, and self-reported community protocols often use 10-20 days. No study has compared course lengths.

Routes of Administration

• Intramuscular (IM): the route used in the monkey study and for the injected dose in the human study.
• Subcutaneous (SC): the route community sources most often describe for the reconstituted 20mg research vial. No Pancragen study we found used it.
• Oral: one rat study gave Pancragen by mouth and reported a pronounced glucose-lowering effect (Khavinson et al., 2007, PMID 18642713). The human study paired an oral dose with the injection.

US vendors sell the 20mg vial labeled for laboratory research only.

Reconstitution Quick Reference

The community-circulated arithmetic: 20mg ÷ 2mL = 10mg/mL, so 2mg is 0.2mL, or 20 units on a 100-unit insulin syringe. By that arithmetic, a 30-day course at the reported amount would total 60mg, or three 20mg vials. The 10 mcg study dose works out to 0.001mL at this concentration, a tenth of one unit, which an insulin syringe cannot measure. Community notes describe swirling gently rather than shaking, then refrigerating at 2-8°C.

These figures report how community sources describe the arithmetic. They are not a preparation instruction. Vendors label these vials for research use only; the schedules on this page are community- and practitioner-reported, not labeled directions.

Affiliate disclosure: vendor links in this article are affiliate links. The Peptide Catalog may earn a commission if you buy through them, at no additional cost to you.

Ready to buy? The Pancragen source we track publishes certificates of analysis; see our Pancragen sources page.

Where These Numbers Come From

Pancragen has more published work than most bioregulators. Nearly all of it comes from the Khavinson research network and its Ukrainian and Russian collaborators. Here is what each study reports.

Rats. The developers synthesized KEDW as an analog of a four-residue fragment common to insulin-related polypeptides. In rats with alloxan-induced diabetes it partly restored insulin synthesis (Khavinson, 2005, PMID 16671579). In streptozotocin-diabetic rats, oral Pancragen lowered blood glucose during treatment. Intramuscular Pancragen normalized capillary endothelial adhesion but did not change capillary permeability (Khavinson et al., 2007, PMID 18642713). A separate rat study reported regulatory effects on pancreatic tissue structure (Kvetnoi et al., 2007, PMID 18225766).

Cell cultures. In aging pancreatic cell cultures, Pancragen raised the expression of the differentiation factors Pdx1, Ptf1a, Pax6, Pax4, Foxa2 and Nkx2.2 (Khavinson et al., 2013, PMID 23486591). A tissue-specificity study found it stimulated differentiation markers in pancreatic cells, while Bronchogen did so in bronchial cells (Khavinson et al., 2012, PMID 22808515).

Monkeys: the 50 mcg dose. Old female rhesus monkeys received 50 mcg per animal per day intramuscularly for 10 days. Glucose was cleared faster after a glucose load, and the insulin and C-peptide responses normalized. Part of the effect remained three weeks after the last dose (Goncharova et al., 2014, PMID 25946840). A follow-up compared the same Pancragen course with glimepiride at 4 mg a day in 9 old monkeys. Both lowered basal glucose. Glimepiride had the stronger and later glucose-lowering effect, while Pancragen normalized insulin and C-peptide (Goncharova et al., 2015, PMID 28509500).

Humans: the 10 mcg dose. A 2011 study compared 30 healthy older adults with 33 older patients with type 2 diabetes. In the diabetic patients, Pancragen lowered fasting glucose and the glucose-tolerance curve, and reduced insulin and an insulin-resistance index. The abstract does not state the dose (Korkushko et al., 2011, PMID 22448364). A 2019 conference abstract (not indexed in PubMed) gives a dose. Sixteen patients aged 60-74 on stable glibenclamide received 10 mcg Pancragen intramuscularly daily for 3 weeks, plus 200 mcg orally. Fasting glucose fell by 1.1 ± 0.4 mmol/L, against 0.3 ± 0.2 mmol/L in 14 patients on glibenclamide alone, and no adverse events were recorded (Shatylo, Korkushko & Khavinson, IAGG-ER 2019 abstract).

How to read this. The human data are small, short and come from collaborators of the compound's developer, and the conference abstract is not peer-reviewed. The studied doses are 10-50 mcg. The 2mg vial protocol is 40-200 times higher and has no study behind it.

Free acid versus amide. The 2005, 2007 and 2010 papers describe the C-terminal amide, Lys-Glu-Asp-Trp-NH2 (Khavinson et al., 2010, PMID 21246099). The Swiss Chems listing gives the formula C26H36N6O9, which matches the free-acid form of KEDW. No published work compares the two.

Extract versus synthetic. The Khavinson program made tissue-derived polypeptide complexes and short synthetic peptides as separate products. The studies above tested synthetic KEDW. Russian oral products sold under bioregulator names are a different format from the 20mg injectable research vial.

Stacking Protocols

Community sources sometimes run Pancragen alongside other Khavinson-family peptides in the same course window. These pairings are self-reported and untested.

No Pancragen combination has been studied. The table reports community descriptions, not a regimen.

Side Effects & Safety

• No adverse events were recorded in the 2019 conference abstract (16 treated patients, 3 weeks). That is a very small and short safety record.
• The consistent signal reported across the rat, monkey and human work is lower blood glucose. In the human study, Pancragen was given on top of an existing sulfonylurea under monitoring.
• Injection-site redness or soreness is the effect most often mentioned in self-reported community sources.
• No safety data exist at the 2mg community dose, which is many times the studied amount.
• Research vials are sold labeled "not for human consumption."

mg to Units Conversion

On a U-100 insulin syringe, 1 unit is 0.01mL. The draw depends on how much water went into the vial.

Dilution A: 20mg vial + 2mL BAC water (10mg/mL)

Dilution B: 20mg vial + 1mL BAC water (20mg/mL), a more concentrated mix with smaller draw volumes

The microgram doses from the published studies cannot be drawn accurately from a 20mg vial at either dilution. Only the 2mg row matches the practitioner figure; the other rows are arithmetic reference points, not amounts a cited source reports. These conversions reflect the dilutions documented in community reconstitution protocols. They report how the math is described, not a recommended dosing schedule.